Original Research PaperDouble-layered osmotic pump controlled release tablets of Actarit (cas 18699-02-0): In vitro and in vivo evaluation

Add time:09/10/2019    Source:sciencedirect.com

The aim of the study was to develop actarit double-layered osmotic pump tablets to overcome the weak points of actarit common tablets, such as short half-life and large plasma concentration fluctuations. Single factor experiment and orthogonal test were applied to optimize the formulation; the pharmacokinetic study was performed in beagle dogs adopting actarit common tablets as reference tablets. The optimal formulation was as follows: drug layer: 150 mg actarit, 240 mg PEO-N80, 50 mg NaCl; push layer: 140 mg PEO-WSR303, 20 mg NaCl; coating solution: 30 g cellulose acetate and 6 g PEG 4000 in 1000 ml 94% acetone solution, 60 mg coating weight gain. The pharmacokinetic study showed that Tmax was prolonged by the contrast of commercial common tablets with constant drug release rate, but the bioavailability was equivalent. And a good in vivo–in vitro correlation of the actarit osmotic pump tablets was also established. The designed actarit osmotic pump tablets can be applied for rheumatoid arthritis, proposing a promising replacement for the marked common products.

We also recommend Trading Suppliers and Manufacturers of Actarit (cas 18699-02-0). Pls Click Website Link as below: cas 18699-02-0 suppliers

Prev:Original articleImidazol-1-yl-acetic acid as a novel green bifunctional organocatalyst for the synthesis of 1,8-dioxooctahydroxanthenes under solvent-free conditions
Next:Original ArticleStability-indicating assay method for determination of Actarit (cas 18699-02-0), its process related impurities and degradation products: Insight into stability profile and degradation pathways☆☆)